Navigation Links
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
Date:6/3/2008

ming of the filing of the BLA; the importance of certain secondary endpoints in the CORD I trial, including the difference between the pre- and post-treatment contracture angles and whether patients achieved at least a 50% reduction in their contracture compared to baseline; the utility of XIAFLEX in the treatment of Dupuytren's contracture, including the potential for XIAFLEX as the first-line treatment option for Dupuytren's contracture; the potential of XIAFLEX to revolutionize the treatment for Dupuytren's contracture; the benefits of XIAFLEX compared to surgery for the treatment of Dupuytren's contracture and the ability of XIAFLEX to address the medical need for a non-surgical treatment for Dupuytren's contracture earlier in the disease process; the period of time during which patients receiving XIAFLEX in the studies will be monitored; and products in development for Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease. All statements other than statements of historical facts contained in this release, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the words "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and similar expressions, as they relate to the Company, constitute forward-looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 under the heading "Risk Factors", which is on
'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 Investor-Edge ... (NASDAQ: NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, ...
(Date:10/31/2014)... (OTCQB:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2015 ... Company posted quarterly net revenue of $2.279 million for ... per share. These results compare to net revenue of ... or $(0.01) per share, in the year-ago quarter. Gross ...
(Date:10/31/2014)... 2014 Research ... of the  "Process Validation in the US and ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to ... Approach to Process Validation for Pharmaceutical and Biopharmaceutical ... FDA Process Validation Guidance EU Process ...
Breaking Medicine Technology:Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... The U.S. Food and Drug Administration today issued draft ... previously cleared 510(k) device require a new premarket submission. ... The 510(k) process is the most common review path ... a device, manufacturers must submit a premarket notification or ...
...   UK pharma group ... quarter but highlights strong underlying sales momentum. ... CEO Andrew Witty and CFO Simon Dingemans review Q2 ... strategy, improving margins and a review of the recently ...
Cached Medicine Technology:FDA Issues Draft Guidance on Device Changes That Warrant New Premarket Review 2
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org ... whose father suffered from Alzheimer's disease. , In fact, ... his father's disease. His father pointed a gun and shot ... when the author of this method understood that he needed ... Memory Healer program is based on years of research. The ...
(Date:10/31/2014)... Lee's Summit, Missouri (PRWEB) October 31, 2014 ... circulated the country about families narrowly escaping carbon monoxide ... winter season) looms just weeks away, one family-owned, Missouri-based ... and straightforward approach to making sure families start the ... systems are safe and secure. , Beginning Nov. ...
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Surgery for low back ... in the United States you live, a new report ... low back pain at some point in their lives, ... medical care for a spine problem," co-author Brook Martin, ... Practice, said in a college news release. In ...
(Date:10/31/2014)... is a major contributor to deaths caused by motor ... underscore the importance of the "Sleep Well, Be Well" ... Results show that the risk of unintentional fatal injury ... insomnia symptoms present. People with all three symptoms of ... a fatal injury than those with no insomnia symptoms, ...
(Date:10/31/2014)... The Suspension Revolution review published by ... developed by Dan Long, a suspension training specialist. ... professional and life coach. The author of this program ... is not impossible , The Suspension Revolution review reveals ... training promises efficiency when it comes to burning fat, ...
Breaking Medicine News(10 mins):Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2
... a non-profit organization focused on supporting innovative early ... at its fall Fellowship Award Committee review. ... outstanding postdoctoral scientists conducting basic and translational cancer ... across the country. The Fellowship encourages the nation,s ...
... Mozes HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay ... amounts of vigorous physical exercise appear to lower their risk ... hours a week or more of vigorous biking, tennis, jogging ... the research team found. But they added that even moderate ...
... 5 (HealthDay News) -- The number of American adults treated for ... 9 million to 19 million, says a federal government report released ... diabetes increased from 4.3 million to 8 million among people age ... 45 to 64; and 1.2 million to 2.4 million among people ...
... Gehrig,s disease, or amyotrophic lateral sclerosis (ALS), and frontotemporal ... brain and spinal-cord cells that include an RNA-binding protein ... of the lesions formed by these clumps. ... Clinical Investigation , a team led by Virginia M.-Y. ...
... HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay News) ... be treatable with a vaccine that has been engineered ... with a cocaine-like substance that mimics cocaine,s molecular composition. ... effective and long-lasting antibody immune response, attacking cocaine molecules ...
... at Mount Sinai School of Medicine has developed the ... This instrument has recently been used by soldiers returning ... in the Sixth Annual Road to Recovery Conference and ... TBI. "Traumatic brain injury is underdiagnosed, and ...
Cached Medicine News:Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 4Health News:Exercise May Improve Odds Against Prostate Cancer Death 2Health News:Exercise May Improve Odds Against Prostate Cancer Death 3Health News:Exercise May Improve Odds Against Prostate Cancer Death 4Health News:Diabetes Soaring Among American Adults: Report 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 3Health News:Mount Sinai develops first screening tool for war veterans to assess traumatic brain injury 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: